65,437 trials
Obesity
Primary: Visceral Fat Volume With Automated Analysis — 994 cubic centimeters
Education, Medical, Undergraduate · Medical History Taking · Diagnosis
Primary: Developing an Appropriate Treatment Plan (for Contextual Variant of Encounters) — 0.67; 0.24 proportion of contextual encounters — p=<0.001
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-positive Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate — 44; 41 percentage of participants
Major Depressive Disorder
Primary: Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET) — -8.42; -9.28; -8.92 Units on a scale — p=0.175
Rheumatoid Arthritis
Primary: Response to Intravenous Canakinumab and Oral Methotrexate (MTX) Compared to MTX Alone as Determined by 50% Improvement in Symptoms According to the American College of…
Ketamine Adverse Reaction · Effects of; Anesthesia, Spinal and Epidural, in Pregnancy · Complication of Labor and/or Delivery
Primary: Number of Subjects Requiring Supplemental Analgesia in the First 24 Hours Following Cesarean Delivery — 64; 66 participants — p=0.86
Attention Deficit Hyperactivity Disorder
Primary: Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Intent-to-Treat (ITT) Population — 0.97; 1.01 Units on a scale
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Gout
Primary: Core Study: Mean Number of Gout Flares Per Participant — 0.5; 0.4; 0.2; 0.4 Gout flares
Multiple Sclerosis
Primary: Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk) — 6; 78 Participants
Opiate Dependence · Drug Dependence · Substance Dependence
Primary: Responders at Day 3 — 85; 85; 8; 9 Participants
Panic Disorder
Primary: Mean Change From Baseline in Panic and Agoraphobia Scale (PAS) Total Score at the End of Treatment Phase — -17.4; -17.0 Scores on scale
Schizophrenia
Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants
Coitus
Primary: Number of Participants Showing Change From Baseline in Irritation Scores — 0; 0 Participants
Systemic Lupus Erythematosus
Primary: SLE Responder Index (SRI) Response Rate at Week 52 — 33.5; 40.6; 43.2 Percentage of participants — p=0.0167